CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine's Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer

Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors which most often show longer survival in a proportion of patients with a higher level of tumor cell PD-L1 expression



Combination therapy could boost patient outcomes



CEL-SCI has filed a patent for the use of Multikine in tumor expressing low levels of PD-L1

Related Keywords

United States ,Montreal ,Quebec ,Canada ,Virginia ,Maryland ,Baltimore ,Vienna ,Wien ,Austria ,United Kingdom ,American ,Philip Lavin ,Exchange Commission ,Securities Exchange ,International Conference On Head ,European Union ,Neck Cancer Society ,Drug Administration ,American Head ,Annual International Conference ,Neck Cancer ,Leukocyte Interleukin Injection ,Programmed Death Ligand ,Leukocyte Interleukin ,Orphan Drug ,Securities Act ,Securities Exchange Act ,Markets ,